Laura Arechabala-Palacios's scientific contributions

What is this page?

This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (1)

Figure 1. Flow diagram. Diagram showing the flow of patients throughout the study.
Figure 2. Demographics of the series. It is grouped by 5-year age ranges. Weight is measured in kilograms, height in meters and BMI is grouped into 4 ranges (corresponding to underweight, normal weight, overweight and obesity). Gravidity (pregnancy) is determined in ranges of 1, 2 and greater than or equal to 3 and parity in ranges of 0, 1 or 2 and greater than or equal to 3.
Figure 4. Comparison of risk factors between first and third trimester. Variation in the number of cigarettes consumed per day; antenatal risk factors; the number of patients with low, intermediate and high risk; the number of participants with positive variables in low risk (0, 1, 2, 3, 4 or 5); the number of pregnant women with LMWH prophylaxis and how many of these women had indication for it due to COVID-19; the number of patients with prescription of ASA and how many of these patients had indication for ASA due to risk of preeclampsia.
Figure 5. Types of delivery. Pie chart showing the proportion of each type of delivery: eutocic (natural childbirth), cesarean section scheduled or decided during labor, and instrumental rotator delivery
Pilot study on the use of low molecular weight heparins in the prevention of thromboembolic disease during pregnancy and puerperium
  • Preprint
  • File available

April 2022

·

88 Reads

Paloma Anchústegui-Mendizábal

·

Patricia Anchústegui-Mendizábal

·

Laura Arechabala-Palacios

·

[...]

·

A pregnant woman is 4 to 5 times more likely to suffer a thromboembolic event than a non-pregnant woman. Furthermore, an increase in these episodes has been observed in women infected with SARS-CoV-2 . Consequently, the prophylactic prescription of low-molecular-weight heparins (LMWH) in pregnant women is undergoing an increase that has not been evaluated yet. The aim of this study was to determine the prevalence of LMWH prescription in pregnant women at the Hospital Universitario Puerta de Hierro Majadahonda (HUPHM), according to their level of risk and its variation due to SARS-CoV-2 infection. To answer this question, a retrospective cohort of 113 women who gave birth during the month of February at the HUPHM was designed. The level of individual risk of thromboembolism, according to the Royal College guidelines (37a), was calculated with an interview to complete a questionnaire and the analysis of their clinical records. 53.6% of the women were prescribed LMWH as indicated in the guidelines. This high prevalence is explained by the high age of the pregnant women (over 35 years), the wave of the omicron variant (December 2021) and a high rate of cesarean sections (25%). On the other hand, the percentage of patients with COVID-19 was 17.6% but only 53% of them had received LMWH. In conclusion, LMWH is a very common prescription in obstetrics, mostly during puerperium, and has become even more relevant due to the COVID-19 pandemic

Download
Share